Whole-cell cancer vaccination: From autologous to allogeneic tumor- and dendritic cell-based vaccines

Cancer Immunology, Immunotherapy

Volumn 57, Issue 10, 2008, Pages 1569-1577

  De Gruijl, Tanja D ^a   Van Den Eertwegh, Alfons J M ^a   Pinedo, Herbert M ^a   Scheper, Rik J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allogeneic; Autologous; Dendritic cell; Whole cell tumor vaccine

Indexed keywords

2,4 DINITROPHENOL; ALPHA INTERFERON; BCG VACCINE; CPG 7909; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; DOCETAXEL; FLUOROURACIL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; PREDNISONE; PROVENGE; TUMOR CELL VACCINE;

ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FLU LIKE SYNDROME; HUMAN; INJECTION SITE REACTION; INJECTION SITE ULCER; KIDNEY CARCINOMA; MELANOMA; METASTASIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; T LYMPHOCYTE; TUMOR IMMUNITY;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 48149104076     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0536-z     Document Type: Conference Paper

References (63)

1. A Baars AME Claessen AJM van den Eertwegh HE Gall AG Stam S Meijer G Giaccone CJ Meijer RJ Scheper J Wagstaff JB Vermorken HM Pinedo 2000 Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients Ann Oncol 11 965 970
2. J Banchereau AK Palucka M Dhodapkar S Burkeholder N Taquet A Rolland S Taquet S Coquery KM Wittkowski N Bhardwaj L Pineiro R Steinman J Fay 2001 Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine Cancer Res 61 6451 6458
3. D Berd T Sato HC Maguire Jr J Kairys MJ Mastrangelo 2004 Immunopharmacologcal analysis of an autologous, hapten-modified human melanoma vaccine J Clin Oncol 22 403 415
4. ID Davis M Jefford P Parente J Cebon 2003 Rational approaches to human cancer immunotherapy J Leukoc Biol 73 3 29
5. TD de Gruijl SA Luykx-de Bakker BW Tillman AJ van den Eertwegh J Buter SM Lougheed GJ van der Bij AM Safer HJ Haisma DT Curiel RJ Scheper HM Pinedo WR Gerritsen 2002 Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors J Immunol 169 5322 5331
6. TD de Gruijl OJ Ophorst J Goudsmit S Verhaagh SM Lougheed K Radosevic MJ Havenga RJ Scheper 2006 Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T-Cell-stimulating skin-emigrated dendritic cells J Immunol 177 2208 2215
7. IJ de Vries DJ Krooshoop NM Scharenborg WJ Lesterhuis JH Diepstra GN Van Muijen SP Strijk TJ Ruers OC Boerman WJ Oyen GJ Adema CJ Punt CG Figdor 2003 Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state Cancer Res 63 12 17
8. ML Disis H Bernhard FM Shiota SL Hand JR Gralow ES Huseby S Gillis MA Cheever 1996 Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines Blood 88 202 210
9. G Dranoff E Jaffee A Lazenby P Golumbek H Levitsky K Brose V Jackson H Hamada D Pardoll RC Mulligan 1993 Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting immunity Proc Natl Acad Sci USA 90 3539 3543
10. G Dranoff 2002 GM-CSF-based cancer vaccines Immunol Rev 188 147 154
11. R Eager J Nemunaitis 2005 GM-CSF gene-transduced tumor vaccines Mol Ther 12 18 27
12. JG Egen MS Kuhns JP Allison 2002 CTLA-4: new insights into its biological function and use in tumor immunotherapy Nat Immunol 3 611 618
13. JW Fabre 2001 The allogeneic response and tumor immunity Nat Med 7 649 652
14. G Ferlazzo A Wesa WZ Wei A Galy 1999 Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T-cells J Immunol 163 3597 3604
15. JL Fox 2007 Uncertainty surrounds cancer vaccine review at FDA Nat Biotech 25 827 828
16. WR Gerritsen AJM van den Eertwegh TD de Gruijl G Giaccone RJ Scheper N Sacks T Harding I Lowy E Stankevich K Hege 2007 Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC) ASCO Meeting Abstr 25 5120
17. MG Hanna Jr LC Peters 1978 Immunotherapy of established micrometastases with a bacillus Calmette-Guerin tumour cell vaccine Cancer Res 38 204 209
18. MG Hanna Jr JS Brandhorst LC Peters 1979 Active specific immunotherapy of residual micrometastases: an evaluation of sources, doses and ratios of BCG with tumour cells Cancer Immunol Immunother 7 165 173
19. MG Hanna HC Hoover JB Vermorken JE Harris HM Pinedo 2001 Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumour cell vaccine: first randomized phase III trials show promise Vaccine 19 2576 2582
20. JE Harris L Ryan HC Hoover Jr RK Stuart MM Oken AB Benson 3rd E Mansour DG Haller J Manola MG Hanna Jr 2000 Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumour cell vaccine: eastern cooperative oncology group study E5283 J Clin Oncol 18 148 157
21. H Hasebe H Nagayama K Sato M Enomoto Y Takeda TA Takahashi K Hasumi M Eriguchi 2000 Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients Biomed Pharmacother 54 291 298
22. KM Hege K Jooss D Pardoll 2006 GM-CSF gene-modified cancer cell immunotherapies: of mice and men Int Rev Immunol 25 321 352
23. L Holtl R Ramoner C Zelle-Rieser H Gander T Putz C Papesh W Nussbaumer C Falkensammer G Bartsch M Thurnher 2005 Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide Cancer Immunol Immunother 54 663 670
24. HC Hoover Jr JS Brandhorst LC Peters MG Surdyke Y Takeshita J Madariaga LR Muenz MG Hanna Jr 1993 Adjuvant active specific immunotherapy for human colorectal cancer: 6.5- year median follow-up of a phase III prospectively randomized trial J Clin Oncol 11 390 399
25. ZB Hu W Ma M Zaborski R MacLeod H Quentmeier HG Drexler 1996 Establishment and characterization of two novel cytokine-responsive acute myeloid and monocytic leukemia cell lines, MUTZ-2 and MUTZ-3 Leukemia 10 1025 1040
26. AA Hurwitz BA Foster ED Kwon T Troung EM Choi NM Greenberg MB Burg JP Allison 2000 Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade Cancer Res 60 2444 2448
27. I Hus J Rolinski J Tabarkiewicz K Wojas A Bojarska-Junak J Greiner K Giannopoulos A Dmoszynska M Schmitt 2005 Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia Leukemia 19 1621 1627
28. EM Jaffee RH Hruban B Biedrzycki D Laheru K Schepers PR Sauter M Goemann J Coleman L Grochow RC Donehower KD Lillemoe S O'Reilly RA Abrams DM Pardoll JL Cameron CJ Yeo 2001 Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumour vaccine for pancreatic cancer: a phase I trial of safety and immune activation J Clin Oncol 19 145 156
29. E Jager M Ringhoffer HP Dienes M Arand J Karbach D Jager C Ilsemann M Hagedorn F Oesch A Knuth 1996 Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo Int J Cancer 67 54 62
30. D Jocham A Richter L Hoffmann K Iwig D Fahlenkamp G Zakrewski E Schmitt T Dannenberg W Lehmacher J von Wietersheim C Doehn 2004 Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial The Lancet 363 594 599
31. AM Krieg 2003 CpG motifs: the active ingredient in bacterial extracts? Nat Med 9 831 835
32. AM Krieg 2006 Therapeutic potential of Toll-like receptor 9 activation Nat Rev Drug Discov 5 471 484
33. Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJ (2008) Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol [Epub ahead of print]
34. AJ Masterson CC Sombroek TD de Gruijl YM Graus HJ van der Vliet SM Lougheed AJ van den Eertwegh HM Pinedo RJ Scheper 2002 MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors Blood 100 701 703
35. A Michael G Ball N Quatan F Wushishi N Russell J Whelan P Chakraborty D Leader M Whelan H Pandha 2005 Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables Clin Cancer Res 11 4469 4478
36. AR Neves LF Ensina LB Anselmo KR Leite AC Buzaid LH Camara-Lopes JA Barbuto 2005 Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell-autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions Cancer Immunol Immunother 54 61 66
37. DP Petrylak RB Macarthur J O'Connor G Shelton T Judge J Balog C Pfaff E Bagiella D Heitjan R Fine N Zuech I Sawczuk M Benson CA Olsson 1999 Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer J Clin Oncol 17 958 967
38. G Ratzinger J Baggers MA de Cos J Yuan T Dao JL Reagan C Munz G Heller JW Young 2004 Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming than do dermal-interstitial or monocyte-derived dendritic cells J Immunol 173 2780 2791
39. SJAM Santegoets MW Schreurs AJ Masterson YP Liu S Goletz H Baumeister EW Kueter SM Lougheed AJ van den Eertwegh RJ Scheper E Hooijberg TD de Gruijl 2006 In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line Cancer Immunol Immunother 55 1480 1490
40. SJAM Santegoets AJ Masterson PC van der Sluis SM Lougheed DM Fluitsma AJ van den Eertwegh HM Pinedo RJ Scheper TD de Gruijl 2006 A CD34(+) human cell line model of myeloid dendritic cell differentiation: evidence for a CD14(+) CD11b(+) Langerhans cell precursor J Leukoc Biol 80 1337 1344
41. SJAM Santegoets HJ Bontkes AGM Stam F Bhoelan JJ Ruizendaal AJM van den Eertwegh E Hooijberg RJ Scheper TD de Gruijl 2008 Inducing anti-tumor T-cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model J Immunol 180 4540 4549
42. DM Savarese S Halabi V Hars WL Akerley ME Taplin PA Godley A Hussain EJ Small NJ Vogelzang 2001 Phase II study of docetaxel, estramustine, low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B J Clin Oncol 19 2509 2516
43. WM Siders KL Vergilis C Johnson J Shields JM Kaplan 2003 Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells Mol Ther 7 498 505
44. JW Simons MA Carducci B Mikhak M Lim B Biedrzycki F Borellini SM Clift KM Hege DG Ando S Piantadosi 2006 Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer Clin Cancer Res 12 3394 3401
45. EJ Small PF Schellhammer CS Higano CH Redfern JJ Nemunaitis FH Valone SS Verjee LA Jones RM Hershberg 2006 Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 3089 3094
46. EJ Small N Sacks J Nemunaitis WJ Urba E Dula AS Centeno WG Nelson D Ando C Howard F Borellini M Nguyen K Hege JW Simons 2007 Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer Clin Cancer Res 13 3883 3891
47. EJ Small NS Tchekmedyian BI Rini L Fong I Lowy JP Allison 2007 A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 1810 1815
48. T Suzuki T Fukuhara M Tanaka A Nakamura K Akiyama T Sakakibara D Koinuma T Kikuchi R Tazawa M Maemondo K Hagiwara Y Saijo T Nukiwa 2005 Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells Clin Cancer Res 11 58 66
49. PJ Tacken IJ de Vries R Torensma CG Figdor 2007 Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting Nat Rev Immunol 7 790 802
50. A Tamir E Basagila A Kagahzian L Jiao S Jensen J Nicholls P Tate G Stamp F Farzaneh P Harrison H Stauss AJ George N Habib RI Lechler G Lombardi 2007 Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors Cancer Immunol Immunother 56 2003 2016
51. Y Tanaka S Koido D Chen SJ Gendler D Kufe J Gong 2001 Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice Clin Immunol 101 192 200
52. PE Tarr 1996 Granulocyte-macrophage colony-stimulating factor and the immune system Med Oncol 13 133 140
53. RH Thompson JP Allison ED Kwon 2006 Anti-cytotoxic t lymphocyte (CTLA-4) immunotherapy for the treatment of prostate cancer Urol Oncol 24 442 447
54. BW Tillman TL Hayes TD de Gruijl JT Douglas DT Curiel 2000 Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model Cancer Res 60 5456 5463
55. U Trefzer G Weingart Y Chen G Herberth K Adrian H Winter H Audring Y Guo W Sterry P Walden 2000 Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma Int J Cancer 85 618 626
56. U Trefzer G Herberth K Wohlan A Milling M Thiemann T Sherev K Sparbier W Sterry P Walden 2004 Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients Int J Cancer 110 730 740
57. U Trefzer G Herberth K Wohlan A Milling M Thiemann T Sharav K Sparbier W Sterry P Walden 2005 Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results Vaccine 23 2367 2373
58. T Yasuda T Kamigaki K Kawasaki T Nakamura M Yamamoto K Kanemitsu S Takase D Kuroda Y Kim T Ajiki Y Kuroda 2007 Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma Cancer Immunol Immunother 56 1025 1036
59. AJM van den Eertwegh RJ Lensen RJ Scheper G Giaccone CJLM Meijer HJ Bontkes TD Gruijl E Hooijberg 2006 Autologous tumor cell vaccination with PF-3512676 (CPG 7909) and GM-CSF followed by subcutaneous PF-3512676 and IFN-alpha for patients with metastatic renal cell carcinoma ASCO Meeting Abstr 24 2530
60. A van Elsas AA Hurwitz JP Allison 1999 Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J Exp Med 190 355 366
61. A van Elsas RP Sutmuller AA Hurwitz J Ziskin J Villasenor JP Medema WW Overwijk NP Restifo CJM Melief R Offringa JP Allison 2001 Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy J Exp Med 194 481 489
62. JB Vermorken AM Claessen H van Tinteren HE Gall R Ezinga S Meijer RJ Scheper CJLM Meijer E Bloemena JH Ransom MG Hanna Jr HM Pinedo 1999 Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial Lancet 353 345 350
63. Anonymous (2008) The regulator disapproves. Nat Biotechnol 26:1